For the current week, the overall ratings of eight Biotechnology stocks are worse, according to the database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Achillion (NASDAQ:) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Sales Growth, ACHN also gets F’s. As of Jan. 16, 2013, 16.2% of outstanding Achillion shares were held short. .
This is a rough week for Nymox Pharmaceutical (NASDAQ:). The company’s rating falls to D from the previous week’s C. Nymox Pharmaceutical is engaged in therapeutics in development for enlarged prostate, E. coli, Alzheimer’s disease and other indications and diagnostics for tobacco exposure, and other conditions. .
ZIOPHARM Oncology (NASDAQ:) earns a D this week, moving down from last week’s grade of C. ZIOPHARM Oncology is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The stock gets F’s in Earnings Momentum, Equity, and Cash Flow. As of Jan. 16, 2013, 14.5% of outstanding ZIOPHARM Oncology shares were held short. .
Amicus Therapeutics (NASDAQ:) is having a tough week. The company’s rating falls from C to a D. Amicus Therapeutics is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. The stock receives F’s in Earnings Revisions, Equity, Cash Flow, and Sales Growth. The stock price has fallen 32% over the past month, worse than the 4.7% increase the Nasdaq has seen over the same period of time. .
Idenix Pharmaceuticals
(NASDAQ:) experiences a ratings drop this week, going from last week’s C to a D. Idenix Pharmaceuticals is a biopharmaceutical company that discovers and develops drugs for the treatment of human viral and other infectious diseases. The stock also rates an F in Equity. .
ArQule’s (NASDAQ:) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). ArQule is a biotechnology company that is engaged in the research and development of cancer therapeutics. The stock also gets an F in Sales Growth. Wall Street appears to agree with the stock downgrade, with share prices dropping 12.2% over the past month. .
The rating of Elan (NYSE:) slips from a D to an F. Elan engages in research, development, and commercial activities primarily in the areas of Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). The stock gets F’s in Earnings Revisions and Equity. .
The rating of Curis Inc. (NASDAQ:) declines this week from a D to an F. Curis is a drug discovery and development company that engages in the research and development of cancer therapeutics. The stock’s trailing PE Ratio is 112.30. .
91抖阴’s proprietary stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool .
